Holen Sie sich die Stockscreener-App
57.33
1.83%
1.03
Handel nachbörslich:
57.54
0.21
+0.37%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Principal Financial Group Inc. - MarketBeat
M&T Bank Corp Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb licenses Bioarctic’s Aβ antibody program - BioWorld Online
Bristol-Myers Squibb Stock Will Handle Patent Cliff And Is Still Undervalued (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb licenses amyloid-beta antibody programme - European Pharmaceutical Review
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘This Stock Has Been Hot Since The Summer’ - Yahoo Finance
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol Myers Squibb Stock Earns 83 RS Rating - Yahoo! Voices
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game - Yahoo Finance UK
Fangzhou partners with Bristol Myers Squibb in China - The Pharma Letter
One Community at a Time: Enabling Early Lung Cancer Detection Across the U.S. - CSRwire.com
Bristol Myers Squibb selects novel ALS target under Insitro collaboration - BioWorld Online
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income - The Motley Fool
Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer - The Bakersfield Californian
Bristol Myers enters $100M PyroGlu-Ass license agreement with BioArctic - TipRanks
Leqembi creator to work with Bristol Myers in $1.3 billion deal - The Pharma Letter
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025 - The Bakersfield Californian
JPMorgan optimistic on Bristol-Myers Squibb shares as valuation discounts peer comparisons - Investing.com
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare - BioSpace
BioArctic Inks Massive $1.35B Alzheimer's Drug Deal with Bristol Myers Squibb - StockTitan
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Here is the full article based on the provided information: - Investing.com
Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now? - Yahoo Finance
Bristol Myers Squibb Foundation Launches Major Lung Cancer Screening Initiative with $9.3M Investment - StockTitan
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers Squibb Awards $25M Milestone Payment for Breakthrough ALS Treatment Target Discovery - StockTitan
Urothelial Cancer Drugs Markets and Competitive Landscape - GlobeNewswire
Is Bristol-Myers Squibb Company (BMY) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline - Yahoo Finance
ASH: Out With The Old, In With The New As BMS Ushers In CELMoD Class - Citeline News & Insights
Bristol-Myers Climbs After Jefferies Upgrades Stock On Schizophrenia Drug’s $10B Potential: Retail Is Excited - MSN
Bristol Myers Squibb Co. stock rises Monday, still underperforms market - MarketWatch
Jefferies Upgrades Bristol Myers Squibb to ‘buy’ on drug Cobenfy - Investing.com
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Bristol-Myers Squibb (NYSE:BMY) Rating Increased to Buy at Jefferies Financial Group - MarketBeat
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review - Endpoints News
Wellington Management Group LLP Sells 16,518 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Car T Cell Therapy Market Overall Study Report 2024-2031 | - openPR
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com India
Bristol-Myers Squibb (NYSE:BMY) Will Pay A Larger Dividend Than Last Year At $0.62 - Yahoo Finance
Exome Asset Management LLC Makes New $4.04 Million Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb (BMY) Stock Moves -0.89%: What You Should Know - Yahoo Finance
Padlock investors sue Bristol Myers; Dietmar Berger is Gilead’s new CMO - BioPharma Dive
Global Breakthrough Therapy Designation Market Set to Double by 2029 with Notable CAGR of 13.80% - GlobeNewswire
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Retirement Systems of Alabama - MarketBeat
Inspire Trust Co. N.A. Buys 29,044 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Peapack Gladstone Financial Corp Sells 70,311 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Wilmington Savings Fund Society FSB - MarketBeat
Why Bristol-Myers Squibb (BMY) Is Among the Best Long-Term Dividend Stocks to Invest in Right Now - Yahoo Finance
Bristol Myers Squibb's SWOT analysis: stock faces challenges amid pipeline promise - Investing.com
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT
Arvest Bank Trust Division Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent - BioSpace
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Stock Yards Bank & Trust Co. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Te Ahumairangi Investment Management Ltd - MarketBeat
Coldstream Capital Management Inc. Raises Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Toronto Dominion Bank Trims Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Unlocking Cancer Therapy Market Advancements Highlighted by Potential: Key Growth Drivers and Trends for 20... - WhaTech
0.44%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):